The FDA decision on the expanded use of Neurocrine Biosciences Inc.'s (NBIX) INGREZZA to treat patients with chorea associated with Huntington disease is due on August 20, 2023.Huntington's disease (HD) is an inherited and progressive neurodegenerative condition, leading to a combination of movement, cognitive, and psychiatric impairments. Individuals affected by HD often encounter chorea, which is characterized by unusual, sudden, and irregular movements.INGREZZA received its first FDA approval in April 2017 for the treatment of tardive dyskinesia.The drug generated net product sales of $410 million in the first quarter of 2023, up 36% over the year-ago period.NBIX closed Friday’s (Jul.28, 2023) trading at $102.75, up 1.48%.